BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15993066)

  • 1. QSAR of adenosine A3 receptor antagonist 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives using chemometric tools.
    Bhattacharya P; Roy K
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3737-43. PubMed ID: 15993066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists using FA and GFA techniques.
    Bhattacharya P; Leonard JT; Roy K
    Bioorg Med Chem; 2005 Feb; 13(4):1159-65. PubMed ID: 15670924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
    Roy K; Leonard JT; Sengupta C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR by LFER model of cytotoxicity data of anti-HIV 5-phenyl-1-phenylamino-1H-imidazole derivatives using principal component factor analysis and genetic function approximation.
    Roy K; Leonard JT
    Bioorg Med Chem; 2005 Apr; 13(8):2967-73. PubMed ID: 15781406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
    Thomas Leonard J; Roy K
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4467-74. PubMed ID: 16806923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
    Roy K; Leonard JT
    J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring QSAR for substituted 2-sulfonyl-phenyl-indol derivatives as potent and selective COX-2 inhibitors using different chemometrics tools.
    Khoshneviszadeh M; Edraki N; Miri R; Hemmateenejad B
    Chem Biol Drug Des; 2008 Dec; 72(6):564-74. PubMed ID: 19090923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
    J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative QSAR modeling of COX-2 inhibitor 1,2-diarylimidazoles using E-state and physicochemical parameters.
    Chakraborty S; Sengupta C; Roy K
    Indian J Biochem Biophys; 2007 Jun; 44(3):169-75. PubMed ID: 17650586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.
    Catarzi D; Colotta V; Varano F; Calabri FR; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Tralli A; Montopoli C; Moro S
    Bioorg Med Chem; 2005 Feb; 13(3):705-15. PubMed ID: 15653338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques.
    Leonard JT; Roy K
    Bioorg Med Chem; 2006 Feb; 14(4):1039-46. PubMed ID: 16213730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
    Pran Kishore D; Balakumar C; Raghuram Rao A; Roy PP; Roy K
    Bioorg Med Chem Lett; 2011 Jan; 21(2):818-23. PubMed ID: 21163647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
    Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
    J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
    J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR modeling of globulin binding affinity of corticosteroids using AM1 calculations.
    De K; Sengupta C; Roy K
    Bioorg Med Chem; 2004 Jun; 12(12):3323-32. PubMed ID: 15158800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.
    Morizzo E; Capelli F; Lenzi O; Catarzi D; Varano F; Filacchioni G; Vincenzi F; Varani K; Borea PA; Colotta V; Moro S
    J Med Chem; 2007 Dec; 50(26):6596-606. PubMed ID: 18047262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring selectivity requirements for COX-2 versus COX-1 binding of 2-(5-phenyl-pyrazol-1-yl)-5-methanesulfonylpyridines using topological and physico-chemical parameters.
    Chakraborty S; Sengupta C; Roy K
    Indian J Biochem Biophys; 2005 Apr; 42(2):106-12. PubMed ID: 23923570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.
    Moro S; Bacilieri M; Cacciari B; Bolcato C; Cusan C; Pastorin G; Klotz KN; Spalluto G
    Bioorg Med Chem; 2006 Jul; 14(14):4923-32. PubMed ID: 16564691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
    Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
    Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.